Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. (IOVA) is a clinical-stage biotechnology company developing adoptive cell therapies based on tumour-infiltrating lymphocytes (TIL) for solid tumours. Its lead programme, lifileucel, targets cancers such as advanced melanoma and is being explored in other indications including cervical and non-small cell lung cancers. Investors should note Iovance is dependent on clinical trial readouts, regulatory milestones and the development of an industrial-scale manufacturing process for personalised cell therapies. With a market capitalisation of about $821m, the stock tends to exhibit biotech‑style volatility: positive trial or regulatory news can materially re-rate the share price, while setbacks or financing needs can depress it. This summary is educational and not personalised advice; prospective investors should assess their risk tolerance, research the company’s trial data and financial position, and consider seeking regulated financial advice before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Iovance’s stock with a target price of $7.75, indicating strong growth potential.
Financial Health
Iovance Biotherapeutics has stable revenue and cash flow, but lower profit margins raise concerns.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IOVA
Alternative Cancer Therapies Focus Shifts 2025
The FDA's new boxed warning for Johnson & Johnson and Legend Biotech's cancer drug highlights potential safety issues in CAR-T therapies. This could shift focus to companies developing alternative and potentially safer oncology treatments.
Published: October 13, 2025
Explore BasketWhy You’ll Want to Watch This Stock
TIL Immunotherapy Focus
Develops tumour‑infiltrating lymphocyte therapies, a personalised approach for solid tumours; manufacturing and regulatory hurdles remain, so outcomes can vary.
Clinical Catalysts Ahead
Upcoming trial readouts and regulatory decisions could materially move the share price; these are binary events and can drive volatility.
Commercial Opportunity & Risk
If approved, therapies address sizeable oncology markets but require complex manufacturing, payer engagement and scalability — execution risk is significant.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
